AbbVie

AbbVie to Acquire Allergan

AbbVie and Allergan have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction with an equity value of approximately $63 billion. Once the acquisiton is completed, AbbVie will continue maintain its principal executive offices in North Chicago under the leadership of current chairman and CEO Richard A. Gonzalez. Two members of Allergan’s board of directors, including chairman and CEO Brent Saunders, will join AbbVie’s board.

HUMIRA Receives Orphan Drug Designation for HS

HUMIRA Receives Orphan Drug Designation for HS

The U.S. Food and Drug Administration (FDA) granted HUMIRA (adalimumab, AbbVie) orphan drug designation for the investigational treatment of moderate to severe hidradenitis suppurativa (HS)—a painful skin disease for which there is no known cure nor approved medication.

AbbVie's supplemental Biologic License Application seeking FDA approval for the use of HUMIRA for HS is currently under review.